< O O
TO_SEE O O
> O O
CASE O O
SUMMARY O O
: O O
A O O
92-year O O
old O O
white O O
woman O O
who O O
was O O
receiving O O
venlafaxine T O
for O O
management O O
of O O
depression D O
was O O
found O O
to O O
have O O
hyponatremia O O

Touch O O
sensibility O O
was O O
assessed O O
with O O
von O D
Frey O D
's O D
monofilaments O D
in O O
the O O
breasts O O
of O O
10 O O
healthy O O
women O O
( O O
controls O O
) O O
and O O
of O O
80 O O
women O O
with O O
breast D D
cancer D D
who O O
at O O
least O O
1 O O
year O O
previously O O
had O O
undergone O D
subcutaneous T D
mastectomy T D
and O O
immediate O O
reconstruction O O
with O O
a O O
prosthesis O O

Although O O
improved O O
glycemic T O
control T O
, O O
maintenance O O
of O O
normal O D
blood O D
pressure O D
, O O
and O O
use O O
of O O
angiotensin-converting T D
enzyme T D
inhibitors T D
are O O
important O O
strategies O O
to O O
avoid O O
developing O O
microalbuminuria D O
, O O
dietary O O
macronutrient O O
intake O O
may O O
also O O
play O O
a O O
role O O

Local O O
injection O O
of O O
corticosteroids T D
into O D
refractory O D
esophageal O D
strictures O D
to O O
decrease O O
the O O
restenosis D O
rate O O
has O O
been O O
reported O O

We O O
systematically O O
reviewed O O
the O O
evidence O O
concerning O O
the O O
ability O O
of O O
five O O
systemic T O
treatments T O
to O O
induce O O
remission O O
in O O
patients O O
with O O
severe D D
psoriasis D D
: O O
ultraviolet T O
B T O
( T O
UVB T O
) T O
, O O
photochemotherapy T O
( T O
PUVA T O
) T O
, O O
methotrexate T O
( T O
MTX T O
) T O
, O O
retinoids T O
( T O
RET T O
) T O
and O O
cyclosporin T O
A T O
( T O
CYA T O
) T O

Consequently O O
, O O
parenteral T D
nutrition T D
( T O
PN T O
) T O
solutions T O
used O O
to O O
treat O O
malnourished O O
patients O O
with O O
chronic D D
renal D D
failure D D
usually O D
are O O
prepared O O
with O O
little O O
supplementation O O
of O O
these O O
cations O O

< O O
TO_SEE O O
> O O
CONCLUSIONS O O
: O O
Malnourished O O
patients O O
with O O
chronic D D
renal D D
failure D D
receiving O D
PN T O
are O O
at O O
risk O O
of O O
developing O D
electrolyte D D
abnormalities D D
, O O
particularly O D
hypophosphatemia D D

PURPOSE O O
: O O
We O O
report O O
a O O
multicenter O O
experience O O
using O O
tubularized T O
incised T O
plate T O
urethroplastym T O
for O O
proximal D D
hypospadias D D

MATERIALS O O
AND O O
METHODS O O
: O O
From O O
August O O
1993 O O
to O O
December O O
1996 O O
tubularized T D
incised T D
plate T D
urethroplasty T D
was O O
performed O O
in O O
27 O O
boys O O
6 O O
months O O
to O O
3 O O
years O O
old O O
with O O
mid D O
shaft D O
and D O
penoscrotal D D
hypospadias D D

RESULTS O O
: O O
Tubularized T T
incised T T
plate T T
surgery T T
created O T
a O O
functional O O
neourethra O O
even O O
in O O
penoscrotal D D
hypospadias D D

CONCLUSIONS O O
: O O
Tubularized T T
incised T T
plate T T
urethroplasty T T
is O O
a O O
versatile O O
operation O O
that O O
corrects O T
proximal D T
hypospadias D T
defects D O
with O O
few O O
complications O O
and O O
superior O O
cosmetic O O
results O O

Aortocoronary T T
bypass T T
grafting T T
is O O
an O O
accepted O O
procedure O O
for O O
ischemic D D
heart D D
disease D D

Immunotherapy T O
of O O
mice O O
with O O
preexisting O D
cancers D D
with O O
heat T O
shock T D
protein T D
preparations T D
derived T D
from T D
autologous T D
cancer T D
resulted O D
in O O
retarded O O
progression O O
of O O
the O O
primary O D
cancer D D
, O O
a O O
reduced O O
metastatic O O
load O O
, O O
and O O
prolongation O O
of O O
life-span O O

< O O
TO_SEE O O
> O O
Intrapleural T O
injection T O
of T O
irradiated T D
LLC-IL2 T D
cured O D
pre-existing D D
lung D D
LLC D D
tumors D D
and O O
extended O O
the O O
survival O O
of O O
the O O
mice O O
but O O
did O O
not O O
affect O O
survival O O
of O O
mice O O
with O O
pre-existing O D
peritoneal D D
tumors D D
nor O D
did O D
it O O
affect O O
the O O
growth O O
of O O
s.c. D D
tumors D D

< O O
TO_SEE O O
> O O
Intraperitoneal T O
injection T O
of T O
irradiated T D
LLC-IL2 T D
cured O D
pre-existing D D
LLC D D
peritoneal D D
tumors D D
and O O
extended O O
the O O
survival O O
of O O
the O O
mice O O
but O O
did O O
not O O
affect O O
survival O O
of O O
mice O D
bearing O D
lung D D
tumors D D
nor O D
did O D
it O O
affect O O
the O O
growth O O
of O O
s.c. D D
tumors D D

Subcutaneous T O
injection T O
of T O
irradiated T D
LLC-IL2 T D
did O D
not O O
affect O O
the O O
growth O O
of O O
preexisting O D
s.c. D D
tumors D D
and O O
also O O
did O O
not O O
improve O O
survival O O
of O O
mice O O
bearing O O
the O O
lung D O
or D O
peritoneal D O
tumors D O

We O O
describe O O
such O O
an O O
event O O
in O O
a O O
man O O
who O O
underwent O O
allogeneic T O
BMT T O
for O O
APL D O
in O O
second O O
relapse O O
and O O
4 O O
years O O
later O O
presented O O
with O O
testicular O O
relapse O O

Olanzapine T O
is O O
an O O
atypical O D
antipsychotic O D
effective O O
in O O
the O O
treatment O O
of O O
schizophrenic D O
patients D O

After O O
a O O
2- O O
to O O
9-day O O
placebo O O
lead-in O O
, O O
79 O O
inpatients O O
with O O
schizophrenia D D
according O D
to O O
DSM-III-R O O
criteria O O
were O O
placed O O
on O O
an O O
olanzapine T O
dosage O O
of O O
10 O O
mg/day O O
or O O
1 O O
mg/day O O
for O O
up O O
to O O
6 O O
weeks O O

Fludarabine T O
and O O
ara-C T D
successfully O D
eradicated O D
bone D D
marrow D D
disease D D
in O O
16 O O
of O O
27 O O
patients O O
( O O
59 O O
% O O
) O O
, O O
23 O O
patients O O
of O O
which O O
had O O
been O O
treated O O
previously O O
with O O
high-dose O D
ara-C T D

These O O
results O O
verified O O
the O O
synergistic O O
effect O O
fludarabine T O
exhibited O O
in O O
augmenting O D
ara-CTP T D
concentrations O D
in O O
patients O O
' O O
leukemic O O
blasts O O
, O O
thus O O
improving O O
the O O
clinical O O
response O O
in O O
relapsed D O
pediatric D O
leukemias D O

BACKGROUND O O
: O O
The O O
growing O O
use O O
of O O
heparin T O
in O O
acute D D
thrombotic D D
disorders D D
, O O
coupled O O
with O O
the O O
availability O O
of O O
many O O
new O O
antithrombotic T D
agents T D
, O O
emphasizes O O
the O O
need O O
for O O
adequate O O
characterization O O
of O O
the O O
platelet O O
effects O O
of O O
the O O
various O O
anticoagulants T O

METHODS O O
AND O O
RESULTS O O
: O O
Platelet O O
P-selectin O O
( O O
CD62 O O
) O O
and O O
activated O O
GP O O
IIb/IIIa O O
( O O
PAC-1 O O
) O O
expression O O
on O O
platelet O O
membrane O O
was O O
quantified O O
in O O
whole O O
blood O O
as O O
well O O
as O O
platelet O O
aggregation O O
in O O
platelet-rich O O
plasma O O
in O O
43 O O
patients O O
with O O
unstable D D
angina D D
before O O
and O O
during O O
treatment O O
with O O
UFH T O
or O O
enoxaparin T O

PURPOSE O O
: O O
We O O
review O O
our O O
initial O O
experience O O
with O O
direct T D
percutaneous T D
transluminal T D
angioplasty T D
( T O
PTA T O
) T O
as O O
a O O
reperfusion T O
treatment T O
for O O
acute D D
occlusion D D
of D O
the D O
middle D O
cerebral D O
artery D O

< O O
TO_SEE O O
> O O
CONCLUSION O O
: O O
Direct O O
PTA O O
may O O
be O O
performed O O
safely O O
as O O
an O O
alternative O O
to O O
thrombolytic O T
therapy O T
in O O
patients O O
with O O
acute O D
occlusion O D
of O O
the O O
middle O O
cerebral O O
artery O O
when O O
early O O
CT O O
findings O O
and/or O O
lenticulostriate O O
artery O O
involvement O O
are O O
present O O
or O O
when O O
superselective O T
local O T
angiography O T
shows O O
the O O
presence O O
of O O
a O O
large O O
embolus O O
or O O
high-grade O O
stenosis O O

Women O O
randomised O O
to O O
screen-and-treat O O
received O O
appropriate O O
antibiotics T O
only O O
if O O
screening O O
proved O O
positive O O
for O O
one O O
or O O
more O D
infection D D

< O O
TO_SEE O O
> O O
A O O
71-year-old O O
woman O O
with O O
autoimmune O D
hemolytic O D
anemia O D
underwent O D
an O O
emergency O O
endocardial T O
patch T O
repair T O
for O O
ventricular D D
septal D D
perforation D D
after O D
acute O D
myocardial O D
infarction O D

Use O O
of O O
washed T O
red T O
blood T O
cells T O
was O O
effective O O
in O O
averting O D
hemolytic D D
crisis D D
throughout O D
perioperative O D
period O D

Therefore O O
, O O
prudent O O
management O O
and O O
use O O
of O O
washed T O
red T O
blood T O
cells T O
transfusion T D
would O D
prevent O D
hemolytic D D
aggravation D D
even O O
in O O
open O D
heart O D
surgery O D

< O O
TO_SEE O O
> O O
We O O
report O O
a O O
case O O
of O O
a O O
29-year-old O D
male O D
chronic O D
HBV O D
carrier O D
who O O
developed O D
fulminant D D
reactivated D D
HBV D D
infection D D
following O D
intensive O D
chemotherapy T D
for O O
stage D D
IVB D D
large D D
cell D D
B-cell D D
non-Hodgkin D D
's D D
lymphoma D D
associated O D
with O O
extensive O D
central O D
nervous O D
system O D
and O O
bone O O
marrow O O
involvement O O

We O O
advise O O
that O O
lamivudine T O
should O O
be O O
considered O O
during O O
intensive O O
chemotherapy T O
treatment T O
of O O
chronic O D
carriers O D
of O O
HBV D O

OBJECTIVES O O
: O O
The O O
purpose O O
of O O
this O O
analysis O O
was O O
to O O
determine O O
the O O
influence O O
of O O
an O O
additional O D
treatment O D
delay O D
inherent O D
in O O
transfer O O
to O O
an O O
angioplasty O O
center O O
for O O
primary T O
angioplasty T O
of O O
patients O O
with O O
acute D D
myocardial D D
infarction D D
who O O
are O O
first O O
admitted O O
to O O
hospitals O O
without O O
angioplasty O O
facilities O O

BACKGROUND O O
: O O
Several O O
randomized O O
trials O O
have O O
demonstrated O O
the O O
benefits O O
of O O
primary T O
angioplasty T O
in O O
acute D D
myocardial D D
infarction D D

We O O
report O O
the O O
first O O
case O O
( O O
to O O
our O O
knowledge O O
) O O
of O O
an O O
endoscopic T O
removal T O
of O O
a O O
forehead D D
soft D D
tissue D D
mass D D

As O O
the O O
overview O O
shows O O
, O O
both O O
groups O O
of O O
substances O O
are O O
useful O O
for O O
individualized O O
treatment O O
of O O
benign D D
prostatic D D
hyperplasia D D
( D D
BPH D D
) D D
, O O
provided O O
that O O
conservative O O
pharmacological T O
treatment T O
of O O
BPH D O
is O O
basically O O
accepted O O
and O O
that O O
the O O
patients O O
' O O
quality O O
of O O
life O O
is O O
also O O
considered O O

The O O
results O O
of O O
several O O
clinical O O
investigations O O
showed O O
the O O
efficacy O O
and O O
safety O O
of O O
artichoke T D
extracts T D
( T D
Cynara T D
scolymus T D
L. T O
) T O
in O O
the O O
treatment O O
of O O
hepato-biliary D D
dysfunction D D
and D O
digestive D D
complaints D D
, O O
such O O
as O O
sensation O O
of O O
fullness O O
, O O
loss D O
of D O
appetite D O
, O O
nausea D O
and O O
abdominal D O
pain D O

Besides O O
the O O
well-known O D
nonsteroidal T D
antiinflammatory T D
drugs T D
( T O
NSAID T O
) T O
for O O
the O O
treatment O O
of O O
rheumatic D D
pain D D
herbal T D
medicine T D
can O O
also O O
be O O
applied O O
successfully O O

Extracts O O
of O O
the O O
secondary O O
tubers O O
of O O
Devil T D
's T D
Claw T D
( T D
Harpagophytum T D
procumbens T D
) T O
are O O
recommended O O
for O O
the O O
supportive O O
treatment O O
of O O
degenerative D D
painful D D
rheumatism D D

High-dose T T
intravenous T T
immunoglobulin T T
( T T
hdIVIg T T
) T O
is O O
increasingly O O
used O O
to O O
treat O O
a O O
range O O
of O O
inflammatory D O
and D O
autoimmune D D
diseases D D

The O O
current O O
dermatological O O
uses O O
of O O
hdIVIg T D
include O D
the O O
treatment O O
of O O
dermatomyositis D O
and O O
the O O
autoimmune D O
bullous D O
disorders D O
, O O
epidermolysis D D
bullosa D D
acquisita D D
, O O
pemphigoid D O
, O O
and O O
pemphigus D O

Unfortunately O O
, O O
current O O
dermatological O O
uses O O
of O O
hdIVIg O O
have O O
been O O
limited O O
to O O
either O O
uncontrolled O O
trials O O
or O O
anecdotal O O
case O O
reports O O
, O O
except O O
for O O
a O O
single O O
controlled O O
trial O O
of O O
hdIVIg T O
as O O
adjunctive O D
therapy O D
in O O
patients O O
with O O
dermatomyositis D O
, O O
which O O
documented O O
a O O
significant O O
benefit O O

We O O
describe O O
a O O
technique O O
that O O
enables O O
the O O
autologous T O
repair T O
of O O
large D D
midline D D
incisional D D
hernias D D
by O O
restoring O O
the O O
functional O O
musculoaponeurotic O O
support O O
of O O
the O O
abdominal O O
wall O O

OBJECTIVE O O
AND O O
IMPORTANCE O O
: O O
The O O
use O O
of O O
chronic T D
intrathecal T D
morphine T D
for O O
the O O
treatment O O
of O O
intractable D O
, D O
nonmalignant D D
pain D D
is O O
becoming O O
more O O
prevalent O O

METHODS O O
: O O
During O O
a O O
19-month O O
period O O
, O O
seven O O
children O O
with O O
empyema D D
underwent O D
thoracoscopy T D

< O O
TO_SEE O O
> O O
We O O
describe O O
a O O
patient O O
with O O
left D O
cardiac D D
herniation D D
presenting O D
after O D
intrapericardial T D
pulmonectomy T D
for O O
primary D D
lung D D
cancer D D

The O O
growing O O
use O O
of O O
automated T D
night-time T D
dialysis T D
( T O
APD T O
) T O
in O O
peritoneal D O
dialysis D O
over O O
the O O
last O O
few O O
years O O
shows O O
that O O
this O O
method O O
represents O O
a O O
valid O O
alternative O O
to O O
continuous T O
ambulatory T O
peritoneal T O
dialysis T O
( T O
CAPD T O
) T O

La O O
Serna O O
et O O
al O O
. O O
( O O
Lancet O O
1987 O O
; O O
26 O O
: O O
1517 O O
) O O
were O O
the O O
first O O
to O O
treat O O
adults O O
with O O
recurrent D O
pericarditis D O
with O O
colchicine T O
, O O
and O O
were O O
followed O O
by O O
other O O
authors O O

While O O
these O O
findings O O
are O O
observed O O
for O O
all O O
classes O O
of O O
oral O D
drugs O D
, O O
the O O
issue O O
is O O
especially O O
critical O O
for O O
cancer D D
chemotherapy T D
, O O
in O O
which O O
a O O
narrow O O
therapeutic O O
index O O
is O O
frequently O O
observed O O

Treatment O O
for O O
low-grade D D
NHL D D
during O D
the O O
past O O
30 O O
yr O O
has O O
consisted O O
of O O
high-dose T D
radiation T D
and O O
cytotoxic T O
agents T O
, O O
administered O O
alone O O
or O O
in O O
combination O O
, O O
and O O
high-dose T O
therapy T O
with T O
stem T O
cell T O
transplant T O

However O O
, O O
recent O O
clinical O O
use O O
of O O
monoclonal T O
antibodies T O
( T O
mAbs T O
) T O
in O O
patients O O
with O O
low-grade D D
or D D
transformed D D
low-grade D D
NHL D D
has O O
resulted O O
in O O
less O O
toxicity O O
than O O
conventional O O
treatments O O
, O O
as O O
well O O
as O O
response O O
rates O O
that O O
are O O
comparable O O
or O O
superior O O
to O O
those O O
achieved O O
with O O
chemotherapy T O

Therefore O O
, O O
interest O O
is O O
growing O O
in O O
mAbs T O
as O O
therapeutic O O
alternatives O O
for O O
patients O O
with O O
low-grade D D
NHL D D
and O O
those O O
with O O
transformed O D
histology O D

CONCLUSION O O
: O O
The O O
treatment O O
paradigm O O
for O O
NHL D O
is O O
expected O O
to O O
change O O
over O O
the O O
next O O
few O O
years O O
to O O
include O O
radiolabeled T O
mAbs T O
, O O
administered O O
alone O O
or O O
in O O
combination O O
with O O
cytotoxic T D
agents T D

RESULTS O O
: O O
Clinical O O
trials O O
of O O
UFT T O
published O O
in O O
the O O
Western O O
world O O
have O O
included O O
581 O O
patients O O
with O O
colorectal D D
cancer D D

The O O
activity O O
of O O
oral T O
UFT T O
in O O
large-bowel D D
cancer D D
when O O
administered O O
with O O
oral T D
LV T D
( O D
approximately O D
50 O O
mg/dose O O
) O O
has O O
resulted O O
in O O
objective O O
response O O
rates O O
of O O
approximately O O
40 O O
% O O

CONCLUSION O O
: O O
UFT T O
is O O
a O O
fluoropyrimidine T O
active O O
in O O
colorectal D D
cancer D D

BACKGROUND O O
: O O
Adrenalectomy T O
is O O
the O O
current O O
treatment O O
for O O
phaeochromocytoma D O

CONCLUSION O O
: O O
Adrenal-sparing T D
surgery T D
is O O
safe O O
and O O
effective O O
, O O
and O O
may O O
become O O
the O O
treatment O O
of O O
choice O O
in O O
patients O O
with O O
hereditary D D
phaeochromocytoma D D

< O O
TO_SEE O O
> O O
PURPOSE O O
: O O
The O O
purposes O O
of O O
this O O
descriptive O O
, O O
longitudinal O O
study O O
were O O
to O O
evaluate O O
the O O
MacDibbs O O
Mouth O O
Assessment O O
instrument O O
for O O
the O O
assessment O O
of O O
mucositis O O
in O O
the O O
radiation T O
therapy T O
patient O O
being O O
treated O O
for O O
head D O
and D O
neck D D
cancer D D
and O O
to O O
describe O O
the O O
course O O
of O O
radiation-induced D D
mucositis D D
in O O
these O O
patients O O

< O O
TO_SEE O O
> O O
As O O
concomitant D T
thrombocytosis D T
persisted O T
despite O T
treatment O T
with O O
hydroxyurea T O
, O O
the O O
new O O
megakaryocyte T O
inhibitor T O
anagrelide T O
( T O
Agrelin T O
) T O
was O O
administered O O
and O O
led O O
to O O
normalization O O
of O O
the O O
platelet O O
count O O
within O O
11 O O
days O O

Background O O
: O O
Troglitazone T O
is O O
a O O
new O O
drug O O
for O O
the O O
treatment O O
of O O
type D D
2 D D
diabetes D D

< O O
TO_SEE O O
> O O
For O O
a O O
subset O O
of O O
patients O O
with O O
Kaposi D D
's D D
sarcoma D D
who O O
were O O
treated O O
with O O
recombinant T D
interferon T D
alfa-2a T D
, O O
the O O
disease O O
is O O
in O O
complete O O
remission O O
, O O
without O O
opportunistic D O
infection D O
, O O
and O O
they O O
appear O O
to O O
be O O
culture-negative O O
for O O
the O O
etiologic O O
retrovirus O O
that O O
causes O O
their O O
immune D O
deficiency D O

Interferon T O
alfa-2a T O
appears O O
to O O
have O O
antineoplastic O O
efficacy O O
, O O
( O O
and O O
may O O
have O O
antiretroviral O O
efficacy O O
as O O
well O O
) O O
in O O
this O O
epidemic O O
neoplasm D O

In O O
three O O
consecutive O O
Phase O O
II O O
trials O O
of O O
recombinant T D
interferon T D
alfa-2a T D
( O D
rIFN O D
alfa-2a O D
; O O
Roferon-A O D
Hoffmann-La O D
Roche O D
, O O
Nutley O O
, O O
NJ O O
) O O
involving O O
96 O O
patients O O
with O O
advanced D D
malignant D D
melanoma D D
, O O
an O O
overall O O
response O O
rate O O
of O O
22 O O
% O O
was O O
observed O O

As O O
single O O
agent O O
therapy O O
in O O
malignant D D
melanoma D D
, O O
interferon T O
alfa-2a T O
was O O
only O O
marginally O O
useful O O
in O O
most O O
patients O O

Studies O O
with O O
various O D
interferon T D
alpha T D
preparations T D
, O O
including O O
interferons T O
induced O O
in O O
human O O
leukocytes O O
, O O
interferon T O
alfa-N1 T O
, O O
interferon T O
alfa-2a T O
, O O
and O O
interferon T O
alfa-2b T O
, O O
have O O
all O O
provided O O
evidence O O
for O O
modest O O
but O O
reproducible O O
antitumor O O
activity O O
in O O
advanced D D
renal D D
cell D D
carcinoma D D

Preliminary O O
evidence O O
suggests O O
that O O
interferons T O
beta T O
and T O
gamma T O
may O O
also O O
induce O O
regression O O
of O O
metastatic D D
renal D D
cell D D
carcinoma D D

The O O
rationale O O
for O O
antileukemic T D
therapy T D
in O O
hairy D D
cell D D
leukemia D D
is O O
to O O
reduce O O
the O O
significant O O
risk O O
of O O
infection O O
and O O
other O O
potential O O
serious O O
complications O O

Splenectomy T T
presumably O T
alleviates O T
the O O
pancytopenic O O
effect O O
of O O
hypersplenism D O
by O O
removing O O
the O O
preferred O O
site O O
of O O
leukemic O O
cell O O
proliferation O O

Recombinant O O
and O O
natural O O
forms O O
of O O
interferon T O
alpha T O
have O O
been O O
shown O O
to O O
bring O O
about O O
tumor O O
regressions O O
in O O
patients O O
with O O
low-grade D D
non-Hodgkin D D
's D D
lymphoma D D

Current O O
studies O O
using O O
interferon T O
in O O
patients O O
with O O
low-grade D D
non-Hodgkin D D
's D D
lymphomas D D
are O O
evaluating O O
lower O O
, O O
and O O
perhaps O O
better O O
tolerated O O
doses O O
of O O
interferon T O

This O O
approach O O
is O O
being O O
extended O O
to O O
the O O
clinic O O
, O O
and O O
trials O O
are O O
now O O
underway O O
evaluating O O
combinations O O
of O O
interferon T O
and O O
various O O
cytotoxic T O
drugs T O
known O O
from O O
previous O O
studies O O
to O O
be O O
active O O
in O O
patients O O
with O O
low-grade D D
non-Hodgkin D D
's D D
lymphomas D D

While O O
the O O
demonstrated O O
antiviral O O
, O O
antiproliferative O O
, O O
and O O
immunomodulatory O O
properties O O
of O O
interferons T O
have O O
led O O
to O O
a O O
number O O
of O O
theories O O
regarding O O
their O O
potential O O
use O O
in O O
treating O O
individuals O O
with O O
chronic D D
myelogenous D D
leukemia D D
( D O
CML D O
) D O
, O O
their O O
limited O O
availability O O
has O O
prevented O O
thorough O O
clinical O O
investigation O O

The O O
data O O
resulting O O
from O O
these O O
clinical O O
trials O O
indicate O O
that O O
interferon T O
alfa-2a T O
is O O
effective O O
in O O
inducing O D
hematologic O D
remissions O D
in O O
the O O
majority O O
of O O
minimally O O
treated O O
, O O
benign-phase D O
CML D O
, O O
Ph1-positive O O
patients O O

More O O
than O O
1600 O O
patients O O
with O O
neoplastic D D
disorders D D
have O O
received O O
recombinant T D
human T D
interferon T D
alfa-2a T D
( T D
Roferon-A T D
, T O
Hoffmann-La T D
Roche T D
, T O
Nutley T O
, T O
NJ T O
) T O
as O O
part O O
of O O
ongoing O O
or O O
completed O O
clinical O O
trials O O

PURPOSE O O
: O O
A O O
phase O O
I/II O O
trial O O
of O O
docetaxel T O
, O O
cisplatin T O
, O O
fluorouracil T O
( T O
5-FU T O
) T O
, O O
and O O
leucovorin T O
( T O
TPFL5 T O
) T O
induction T O
chemotherapy T O
for O O
patients O O
with O O
locally D D
advanced D D
squamous D D
cell D D
carcinoma D D
of D O
the D O
head D O
and D O
neck D O
( D O
SCCHN D O
) D O

PATIENTS O O
AND O O
METHODS O O
: O O
Twenty-three O O
previously O O
untreated O O
patients O O
with O O
stage D O
III D O
or D O
IV D O
SCCHN D O
and O O
Eastern O T
Cooperative O T
Oncology O T
Group O T
functional O T
status O O
less O O
than O O
or O O
equal O O
to O O
2 O O
were O O
treated O O
with O O
TPFL5 T O

Intrathecal T T
sufentanil T T
provides O T
approximately O T
2 O O
h O O
of O O
excellent O O
labor D O
analgesia O O
with O O
minimal O D
motor O D
blockade O D

OBJECTIVE O O
: O O
We O O
report O O
the O O
results O O
of O O
a O O
double-blind O O
, O O
double-dummy O O
, O O
active-control O O
study O O
designed O O
to O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
lamotrigine T O
( T O
LTG T O
) T O
administered O O
as O O
monotherapy O O
to O O
adult O O
outpatients O O
with O O
partial D O
seizures D O

BACKGROUND O O
: O O
The O O
effectiveness O O
of O O
LTG T O
as O O
add-on O O
therapy O O
for O O
partial D O
seizures D O
in O O
adults O O
has O O
previously O O
been O O
established O O

CONCLUSIONS O O
: O O
We O O
conclude O O
that O O
LTG T O
is O O
effective O O
and O O
well O O
tolerated O O
when O O
administered O O
as O O
monotherapy O O
in O O
adult O O
patients O O
with O O
partial D O
seizures D O

BACKGROUND O O
: O O
Omega3 O O
fatty O O
acids O O
may O O
inhibit O O
neuronal O D
signal O D
transduction O D
pathways O D
in O O
a O O
manner O O
similar O O
to O O
that O O
of O O
lithium T O
carbonate T O
and O O
valproate T O
, O O
2 O O
effective O O
treatments O O
for O O
bipolar D D
disorder D D

The O O
present O O
study O O
was O O
performed O O
to O O
examine O O
whether O O
omega3 T O
fatty T O
acids T O
also O O
exhibit O O
mood-stabilizing O O
properties O O
in O O
bipolar D O
disorder D O

CONCLUSION O O
: O O
Omega3 T O
fatty T O
acids T O
were O O
well O O
tolerated O O
and O O
improved O O
the O O
short-term O O
course O O
of O O
illness O O
in O O
this O O
preliminary O O
study O O
of O O
patients O O
with O O
bipolar D D
disorder D D

Several O O
large-scale O O
trials O O
have O O
firmly O O
established O O
the O O
effectiveness O O
of O O
thrombolytic T D
therapy T D
, O O
beta T O
blockers T O
, O O
and O O
aspirin T O
in O O
the O O
treatment O O
of O O
AMI D O

< O O
TO_SEE O O
> O O
While O O
diastolic D O
left D O
ventricular D O
( D O
LV D O
) D O
dysfunction D O
is O O
frequent O O
and O O
associated O O
with O O
cardiovascular D D
complications D D
in O O
end-stage D D
renal D D
disease D D
treated O O
with O O
dialysis T O
, O O
controversial O O
information O O
exists O O
on O O
diastolic O D
LV O D
function O D
after O D
renal O D
transplantation O D

METHODS O O
: O O
Fluvastatin T O
40 O O
mg O O
daily O O
was O O
administered O O
to O O
25 O O
patients O O
with O O
hypercholesterolaemia D O
for O O
up O O
to O O
24 O O
weeks O O

The O O
inhibitory O O
effect O O
of O O
n-3 T D
polyunsaturated T D
fatty T O
acids T O
on O O
human D D
colorectal D D
cancer D D
has O O
been O O
speculated O O
on O O
from O O
epidemiological O O
data O O
and O O
animal O O
studies O O

We O O
conducted O O
a O O
long-term O O
trial O O
of O O
docosahexanoic T O
acid T O
( T O
DHA T O
) T O
-concentrated T O
fish T O
oil T O
capsules T O
for O O
patients O O
in O O
a O O
high-risk O O
group O O
for O O
colorectal D D
cancer D D

Three O O
patients O O
with O O
FAP D O
and O O
two O O
patients O O
with O O
multiple O O
( O O
more O O
than O O
30 O O
) O O
colorectal D O
polyps D O
were O O
administered O O
DHA-concentrated T O
fish T O
oil T O
capsules_Hlk427554600 T O
( T O
2.2 T O
g T O
of T O
DHA T O
and T O
0.6 T O
g T O
of T O
eicosapentanoic T O
acid T O
( T O
EPA T O
) T O
per T O
day T O
) T O
for O O
one O O
or O O
two O O
years O O

This O O
article O O
reviews O O
current O O
trends O O
in O O
management O O
of O O
esophageal D D
achalasia D D
, O O
highlighting O O
short-term O O
outcome O O
and O O
cost O O
comparisons O O
of O O
three O O
treatments O O
: O O
botulinum T O
toxin T O
injection T O
, O O
pneumatic T O
dilation T O
, O O
and O O
laparoscopic T O
myotomy T O

The O O
clinical O O
application O O
of O O
therapeutic T D
hysteroscopy T D
, O O
mainly O O
in O O
the O O
field O O
of O O
the O O
treatment O O
of O O
abnormal D D
uterine D D
bleeding D D
, O O
started O O
in O O
the O O
1980s O O

< O O
TO_SEE O O
> O O
In O O
this O O
article O O
, O O
evidence O O
of O O
effectiveness O O
and O O
cost-effectiveness O O
of O O
the O O
following O O
procedures O O
is O O
reviewed O O
: O O
( O O
1 O O
) O O
laser T O
treatment T O
of O O
bladder D D
tumors D D
; O O
( O O
2 O O
) O O
extracorporeal O D
shock-wave O D
lithotripsy O D
and O O
percutaneous O T
nephrolithotomy O T
; O O
( O O
3 O O
) O O
laparoscopic T O
treatment T O
of O O
endometriosis D O
; O O
( O O
4 O O
) O O
laparoscopic T O
removal T O
of O O
ovarian D D
cysts D D
; O O
( O O
5 O O
) O O
laparoscopic O O
cholecystectomy O O
; O O
( O O
6 O O
) O O
laparoscopic O D
appendectomy O D
; O O
( O O
7 O O
) O O
catheter T O
treatment T O
of O O
coronary D D
artery D D
disease D D
; O O
( O O
8 O O
) O O
palliation O O
of O O
colon O D
cancer O D
by O O
endoscopic O D
intervention O D
; O O
( O O
9 O O
) O O
treatment O O
of O O
upper D O
gastrointestinal D O
( D O
UGI D O
) D O
bleeding D O
by O O
endoscopic T O
intervention T O
; O O
and O O
( O O
10 O O
) O O
arthroscopic O O
knee O O
surgery O O

Gene T O
therapy T O
of O O
malignant D D
brain D D
tumors D D

Treatment O O
of O O
irritable D D
bowel D D
syndrome D D
with O O
Chinese T D
herbal T D
medicine T D
: O O
a O O
randomized O O
controlled O O
trial O O

Randomised O O
trial O O
of O O
interferon T D
alpha2b T D
plus T D
ribavirin T D
for O O
48 O O
weeks O O
or O O
for O O
24 O O
weeks O O
versus O T
interferon T T
alpha2b T T
plus T T
placebo T T
for O O
48 O O
weeks O O
for O O
treatment O O
of O O
chronic D D
infection D D
with D O
hepatitis D D
C D D
virus D D

Low-molecular-weight T T
heparin T T
for O O
immediate O O
management O O
of O O
thromboembolic D D
disease D D
in O O
pregnancy O O

Tubularized T T
incised T T
plate T T
hypospadias T T
repair T T
for O O
proximal D D
hypospadias D D

Comparison O O
of O O
radical T D
prostatectomy T D
and O O
iodine T O
125 T O
interstitial T T
radiotherapy T T
for O O
the O O
treatment O O
of O O
clinically D D
localized D D
prostate D D
cancer D D
: O O
a O O
7-year O O
biochemical O O
( O O
PSA O O
) O O
progression O O
analysis O O

The O O
effectiveness O O
of O O
acupuncture T O
in O O
treating O D
acute D D
dental D D
pain D D
: O O
a O O
systematic O O
review O O

Correction O O
of O O
cardiac D D
defects D D
through O D
a O O
right T O
thoracotomy T O
in O O
children O O

New O O
technique O O
for O O
mesh T O
repair T O
of O O
paracolostomy D D
hernias D D

Immunotherapy T O
of O O
tumors D O
with O O
autologous T D
tumor-derived T D
heat T D
shock T D
protein T D
preparations T D

Comprehensive T O
modified T O
diet T O
simplifies O O
nutrition T O
management T O
of O O
adults O O
with O O
short-bowel D D
syndrome D D

Extended O O
use O O
of O O
glatiramer T D
acetate T D
( T D
Copaxone T D
) T D
is O O
well O O
tolerated O O
and O O
maintains O O
its O O
clinical O O
effect O O
on O O
multiple D O
sclerosis D O
relapse O O
rate O O
and O O
degree O O
of O O
disability O O

European O O
register O O
of O O
patients O O
with O O
sickle D D
cell D D
disease D D
treated O D
with O O
hydroxyurea T O
is O O
being O O
set O O
up O O

Understanding O O
the O O
culture O O
of O O
prescribing O O
: O O
qualitative O O
study O O
of O O
general O O
practitioners O O
' O O
and O O
patients O O
' O O
perceptions O O
of O O
antibiotics T O
for O O
sore D D
throats D D

Steroid T O
delivery T O
in O O
croup D O

Haematoma T T
block T T
versus O T
intravenous T T
regional T T
anaesthesia T T
in O O
Colles D O
' D O
fractures D O

Direct T T
percutaneous T T
transluminal T T
angioplasty T T
for O O
acute D D
middle D D
cerebral D D
artery D D
occlusion D D

Magnesium T O
sulphate T O
for O O
the O O
control O O
of O O
spasms D O
in D O
severe D O
tetanus D O

Protective O O
effect O O
of O O
pralidoxime T O
on O O
muscle D D
fiber D D
necrosis D D
induced O D
by O O
organophosphate O O
compounds O O

Assessment O O
of O O
atrioventricular T D
junction T D
ablation T D
and T D
VVIR T D
pacemaker T D
versus O D
pharmacological T D
treatment T D
in O O
patients O O
with O O
heart D D
failure D D
and D D
chronic D D
atrial D D
fibrillation D D
: O O
a O O
randomized O O
, O O
controlled O O
study O O

Statins T O
for O O
prevention O O
of O O
stroke D D

Repair O O
of O O
ventral D D
hernias D D
with O O
expanded T D
polytetrafluoroethylene T D
patch T D

Spinal T O
manipulation T O
in O O
the O O
treatment O O
of O O
episodic D D
tension-type D D
headache D D
: O O
a O O
randomized O O
controlled O O
trial O O

Successful O O
treatment O O
with O O
lamivudine T O
for O O
fulminant D D
reactivated D D
hepatitis D D
B D D
infectioN D D
following O D
intensive T D
therapy T D
for O O
high-grade D D
non-Hodgkin D D
's D D
lymphoma D D

Influence O O
of O O
treatment O D
delay O D
on O O
infarct O O
size O O
and O O
clinical O O
outcome O O
in O O
patients O O
with O O
acute D D
myocardial D D
infarction D D
treated O O
with O O
primary T D
angioplasty T D

Should O O
patients O O
with O O
advanced D D
sarcomas D D
be O O
treated O O
with O O
chemotherapy T O
? O O

Plasma T O
exchange T O
and T O
tacrolimus-mycophenolate T O
rescue T O
for O O
acute D D
humoral D D
rejection D D
in O O
kidney O O
transplantation O O

Hyperbaric T T
oxygen T T
therapy T T
for O O
children O O
with O O
cerebral D D
palsy D D

Endoscopic T O
excision T O
of O O
a D O
forehead D O
mass D O

Effect O O
of O O
photodynamic T D
therapy T D
in T O
combination T O
with T O
mitomycin T D
C T D
on O O
a O O
mitomycin-resistant D D
bladder D D
cancer D D
cell O D
line O O

Is O O
conservative T O
surgery T O
for O O
tubal D D
pregnancy D D
preferable O D
to O O
salpingectomy T O
? O O
An O O
economic O O
analysis O O

Laparoscopic T T
cornuostomy T T
in O O
the O O
treatment O O
of O O
interstitial D D
pregnancy D D
with O O
subsequent O D
hysterosalpingography O D

Experimental O O
evaluation O O
of O O
the O O
use O O
of O O
recombinant T D
prourokinase T D
and O O
its O O
immobilized O O
forms O O
in O O
the O O
treatment O O
of O O
postoperative D D
fibrinoid D D
syndrome D D
in O O
ophthalmology O O

In O O
vitro O O
and O O
in O O
vivo O O
comparison O O
between O O
the O O
effects O O
of O O
treatment O O
with O O
adenosine T D
triphosphate T D
and O O
treatment O O
with O O
buthionine T D
sulfoximine T D
on O O
chemosensitization O O
and O O
tumour O O
growth O O
of O O
B16 D O
melanoma D O

Effects O O
of O O
transpupillary T D
thermotherapy T D
on O D
immunological O D
parameters O D
and O O
apoptosis O O
in O O
a O O
case O O
of O O
primary D O
uveal D O
melanoma D O

Is O O
there O O
a O O
rational O O
therapy O O
for O O
symptomatic O O
treatment O O
of O O
benign D D
prostatic D D
hyperplasia D D
with O O
phytogenic T D
drugs T D
? O O
Illustrated O O
with O O
the O O
example O O
of O O
the O O
prostate O O
agent O O
from O O
Serenoa O O
repens O O
( O O
Sabal O O
fructus O O
) O O

Pharmacological O O
and O O
clinical O O
effectiveness O O
of O O
a O O
fixed T O
phytogenic T D
combination T D
trembling T D
poplar T D
( T D
Populus T D
tremula T D
) T O
, T O
true T O
goldenrod T O
( T O
Solidago T O
virgaurea T O
) T O
and T O
ash T O
( T O
Fraxinus T O
excelsior T O
) T O
in O O
mild D O
to D O
moderate D O
rheumatic D O
complaints D O

Therapy O O
of O O
degenerative D D
diseases D D
of D O
the D O
musculoskeletal D D
system D D
with O O
South T D
African T D
devil T D
's T D
claw T D
( T D
Harpagophytum T D
procumbens T D
DC T O
) T O

Treatment O O
strategy O O
for O O
mucin-producing D D
intrahepatic D D
cholangiocarcinoma D D
: O O
value O O
of O O
percutaneous T D
transhepatic T D
biliary T D
drainage T D
and O O
cholangioscopy T O

Strategy O O
for O O
surgical T O
management T O
of O O
ileocolonic D D
anastomotic D D
recurrence D D
in D D
Crohn D D
's D D
disease D D

Nerve-sparing T T
surgery T T
for O O
advanced D D
rectal D D
cancer D D
patients O D
: O O
special O O
reference O O
to O O
Dukes O O
C O O
patients O O

Prognostic O O
factors O O
in O O
patients O O
with O O
locally O D
advanced O D
rectal D D
adenocarcinoma D D
treated O O
with O O
preoperative T D
radiotherapy T D
and O O
surgery T O

Current O T
surgical T T
therapy T T
for O O
bronchiectasis D O

Thoracic T O
surgery T O
for O O
hydatid D D
disease D D

Surgical T O
treatment T O
of O O
postpneumonic D D
empyema D D

Thoracoscopic T T
surgery T T
for O O
pulmonary D D
tuberculosis D D

Thoracoscopic T T
surgery T T
for O O
spontaneous D D
pneumothorax D D

Surgery T O
for O O
chronic D D
thromboembolic D D
pulmonary D D
hypertension D D

Transabdominal T T
extensive T T
esophagogastric T T
devascularization T T
with T O
gastroesophageal T D
stapling T D
for O O
management O O
of O O
noncirrhotic D D
portal D D
hypertension D D
: O O
long-term O O
results O O

Surgical T O
treatment T O
for O O
lung D D
hydatid D D
disease D D

Sliding T D
door T D
technique T D
for O O
the O O
repair O O
of O O
midline D D
incisional D D
hernias D D

One-lung T O
ventilation T O
in O O
patients O O
with O O
difficult D D
airways D D

Thoracoscopy T O
for O O
empyema D O
in O O
children O O

Sex O O
differences O O
in O O
the O O
use O O
of O O
asthma D D
drugs T D
: O O
cross O O
sectional O O
study O O

Conventional T O
treatments T O
for O O
non-Hodgkin D D
's D D
lymphoma D D
: O O
the O O
need O O
for O O
new O O
therapies O O

Adrenal-sparing T T
surgery T T
for O O
phaeochromocytoma D O

Antiplatelet T T
therapy T T
in O O
acute D D
cerebral D D
ischemia D D

Laugier-Hunziker D D
syndrome D D
: O O
case O O
report O O
and O O
treatment O O
with O O
the O O
Q-switched T O
Nd-Yag T O
laser T O

Thoracoscopic T O
operation T O
for O O
secondary D D
pneumothorax D D
under O D
local O D
and O O
epidural O O
anesthesia O O
in O O
high-risk O O
patients O O

Troglitazone-induced D T
hepatic D T
failure D T
leading O T
to O O
liver T O
transplantation T O

A O O
modified O O
technique O O
of O O
tubeless O O
anaesthesia O O
for O O
microlaryngoscopy T O
and T O
bronchoscopy T O
in O O
young O O
children O O
with O O
stridor D O

A O O
randomized O O
trial O O
of O O
Lactobacillus T D
acidophilus T D
BG2FO4 T D
to O O
treat O O
lactose D D
intolerance D D

Treatment O O
of O O
idiopathic D D
thrombopenic D D
purpura D D
in O O
adolescents O O
by O O
intravenous T D
immunoglobulin T D

Azithromycin T T
therapy T T
for O O
scrub D D
typhus D D
during O D
pregnancy O D

Excimer T T
laser T T
assisted T T
in T O
situ T O
keratomileusis T O
for O O
hyperopia D O

Three O O
consecutive O O
phase O O
II O O
studies O O
of O O
recombinant T D
interferon T D
alfa-2a T D
in O O
advanced D D
malignant D D
melanoma D D

Interferon T O
treatment T O
of O O
renal D D
cell D D
carcinoma D D

Current O O
and O O
future O O
uses O O
of O O
recombinant T D
interferon T D
alpha T D
in O O
the O O
treatment O O
of O O
low-grade D D
non-Hodgkin D D
's D D
lymphoma D D

Antimicrobial T T
treatment T T
options O T
in O O
the O O
management O O
of O O
odontogenic D D
infections D D

Recombinant T T
glycoprotein T T
vaccine T T
for O O
the O O
prevention O O
of O O
genital D D
HSV-2 D D
infection D D
: O O
two O O
randomized O O
controlled O O
trials O O

Induction T O
chemotherapy T O
with T O
docetaxel T O
, T O
cisplatin T O
, T O
fluorouracil T O
, T O
and T O
leucovorin T O
for O O
squamous D D
cell D D
carcinoma D D
of O O
the O O
head O O
and O O
neck O O
: O O
a O O
phase O O
I/II O O
trial O O

Low-dose T T
steroids T T
reduce O T
flu-like D T
symptoms D T
at O O
the O O
initiation O O
of O O
IFNbeta-1b O O
in O O
relapsing-remitting O O
MS O O

Study O O
of O O
three O O
different O O
doses O O
of O O
epidural T D
neostigmine T D
coadministered T D
with T O
lidocaine T O
for O O
postoperative D D
analgesia D D

An O O
active-control O O
trial O O
of O O
lamotrigine T D
monotherapy T D
for O O
partial D D
seizures D D

< O O
TO_SEE O O
> O O
Safety O O
of O O
intrathecal T D
sodium T D
nitroprusside T D
for O O
the O O
treatment O O
and O O
prevention O O
of O O
refractory D D
cerebral D D
vasospasm D D
and D O
ischemia D O
in O O
humans O O

The O O
effect O O
of O O
heliox T O
in O O
acute D D
severe D D
asthma D D
: O O
a O O
randomized O O
controlled O O
trial O O
. O O

Long-term O O
survival O O
of O O
patients O O
with O O
unresectable D D
colorectal D D
cancer D D
liver D D
metastases D D
following O D
infusional T D
chemotherapy T D
with T O
5-fluorouracil T O
, T O
leucovorin T O
, T O
oxaliplatin T O
and T O
surgery T O

< O O
TO_SEE O O
> O O
Fatal D O
acute D O
haemolysis D O
in O O
an O O
AIDS D O
patient O O
treated O O
with O O
lindinavir T O

A O O
simplified O O
laparoscopic T O
technique T O
for T O
mesh T O
placement T O
in O O
ventral D D
hernia D D
repair O D

Pharmacological T O
management T O
of O O
acute D D
myocardial D D
infarction D D

Mesenteric D D
venous D D
thrombosis D D
: O O
successful O O
treatment O O
by O O
intraarterial T D
lytic T D
therapy T D

Gene T O
therapy T O
for O O
myocardial D D
angiogenesis D D

Dipyridamole T T
plus T T
aspirin T T
in O O
cerebrovascular D D
disease D D

What O O
is O O
the O O
real O O
role O O
of O O
CD40 O O
in O O
cancer D D
immunotherapy T D
? O O

The O O
effects O O
of O O
oral T O
liarozole T O
on O O
epidermal O D
proliferation O D
and O O
differentiation O O
in O O
severe D O
plaque D O
psoriasis D O
are O O
comparable O O
with O O
those O O
of O O
acitretin T O
. O O

Safety O O
and O O
potential O O
effectiveness O O
of O O
daunorubicin-containing T D
liposomes T D
in O O
patients O O
with O O
advanced D D
recurrent D D
malignant D D
CNS D D
tumors D D

An O O
experimental O O
application O O
of O O
gene T O
therapy T O
for O O
human D D
retinoblastoma D D

Acid T O
suppression T T
therapy T T
in O O
Barrett D D
's D D
esophagus D D
: O O
the O O
importance O O
of O O
pH O O
monitoring O O

Surgical T O
approaches T O
to O O
pediatric D D
defecatory D D
disorders D D

Lutein T O
improves O O
visual O O
function O O
in O O
some O O
patients O O
with O O
retinal D D
degeneration D D
: O O
a O O
pilot O O
study O O
via O O
the O O
Internet O O

Drug O O
information O O
questions O O
and O O
answers O O
: O O
new O O
for O O
psoriasis D O
: O O
colchicine T O

IPPB T O
in O O
severe D D
pulmonary D D
emphysema D D
: O O
limited O O
applications O O

Long-term O O
mortality O O
in O O
patients O O
after O O
a O O
British O O
trial O O
of O O
anticoagulants T O
in O O
acute D D
myocardial D D
infarction D D

Our O O
results O O
in O O
the O O
surgical T O
treatment T O
of O O
habitual D D
shoulder D D
dislocation D D
with O O
special O O
reference O O
to O O
occupational O O
disability O O

Alkaline O O
phosphatase O O
in O O
neutrophil O O
leukocytes O O
of O O
patients O O
with O O
infectious D D
mononucleosis D D
and O O
the O O
effect O O
of O O
corticosteroid T D
therapy T D

Surgical T O
treatment T O
of O O
uterine D D
cervix D D
insufficiency D D
during O D
the O O
2d O O
trimester O O
of O O
pregnancy O O

Physiologic T O
treatment T O
of O O
depressive D D
reactions D D
: O O
a O O
pilot O O
study O O

The O O
use O O
of O O
quinidine T O
sulphate T O
for O O
the O O
treatment O O
of O O
atrial D D
fibrillation D D
in O O
twelve O O
horses O O

Synergism O O
in O O
the O O
chemotherapy T O
of O O
Eimeria D O
infections D O
of O O
chicks O O

Treatment O O
of O O
hydrocele D O
and D O
cysts D O
of D O
the D O
epididymis D O
with O O
sclerosing T D
injections T D
of T O
quinine T O
and T O
urea T O
chlorhydrolactate T O
in O O
a O O
30 O O
per O O
cent O O
solution O O

The O O
single-place T O
caisson T O
in O O
the O O
treatment O O
of O O
decompression D D
accidents D D

Blood O O
volume O O
measurements O O
in O O
burn D D
therapy T D

Phenylbutazone T O
and O O
acute D O
leukemia D O
. O O

The O O
place O O
of O O
surgery T O
in O O
hypertrophic D D
obstructive D D
cardiomyopathy D D
( D D
idiopathic D D
hypertrophic D D
subaortic D D
stenosis D D
) D O

The O O
treatment O O
of O O
autoimmune D D
hemolytic D D
anemia D D
with O O
heparin T O

Effects O O
of O O
clomiphene T D
citrate T D
on O O
endometrial D D
hyperplasia D D
in O O
the O O
premenopausal O O
female O O

Prolonged O O
use O O
of O O
methyldopa T D
in O D
severe D D
hypertension D D
in O O
pregnancy O O

The O O
effects O O
of O O
social O O
class O O
and O O
friends O O
' O O
expectations O O
on O O
oral O D
polio D D
vaccination T D
participation O D

Glutathione O O
S-transferase O O
activity O O
in O O
epithelial D D
ovarian D D
cancer D D
: O O
association O O
with O O
response O O
to O O
chemotherapy T O
and O O
disease O O
outcome O O

Interferon-alpha-2b T O
in O O
the O O
management O O
of O O
patients O O
with O O
relapsed O D
and/or O D
refractory O D
Hodgkin D D
's D D
disease D D

< O O
TO_SEE O O
> O O
Frontal D D
dysfunction D D
blocks O D
the O O
therapeutic O O
effect O O
of O O
THA T O
on O O
attention O O
in O O
Alzheimer D D
's D D
disease D D

Effects O O
of O O
clomipramine T O
on O O
plasma O O
amino O O
acids O O
and O O
serotonergic O O
parameters O O
in O O
panic D O
disorder D O
and D O
depression D O
. O O

Thalidomide T O
for O O
aphthous D D
ulcers D D
in O D
HIV D D
infection D D

Aspirin T T
therapy T T
in O O
diabetes D D
mellitus D D

Combined T T
pancreas-/kidney T T
transplantation T T
as O O
a O O
standard O O
procedure O O
in O O
therapy O O
of O O
kidney D D
failure D D
in D O
type D O
I D O
diabetic D O
patients D O

Corticosteroid T O
injections T O
for O O
sciatica D O

Flutamide T T
plus T T
castration T T
in O O
patients O O
with O O
previously O D
untreated O D
prostate D D
cancer D D

The O O
immediate O O
effectiveness O O
of O O
electrical T D
nerve T D
stimulation T D
and O O
electrical T O
muscle T O
stimulation T O
on O O
myofascial D O
trigger D O
points D O

In O O
vitro O O
radiation-induced O O
apoptosis O O
and O O
tumour O O
response O O
to O O
radiotherapy T O
: O O
a O O
prospective O O
study O O
in O O
patients O O
with O O
non-Hodgkin D D
lymphomas D D
treated O O
by O O
low-dose T O
irradiation T O

Drug T O
therapy T O
for O O
coronary D D
heart D D
disease D D
: O O
the O O
Sheffield O O
table O O

Percutaneous T O
drainage T O
of O O
hydatid D D
cysts D D

Surgery T O
for O O
ectopia D D
lentis D D

< O O
TO_SEE O O
> O O
Antiplatelet T T
therapy T T
to O O
prevent O O
stroke D O
: O O
risk O O
of O O
brain D D
hemorrhage D D
and O O
efficacy O O
in O O
atrial T O
fibrillation T O

High-dose T T
chemotherapy T T
with T O
autologous T D
hematopoietic T D
stem-cell T D
support T D
for O O
breast D D
cancer D D
in O O
North O O
America O O

Is O O
concomitant T O
radiotherapy T O
and T O
chemotherapy T T
superior O T
to O O
optimal O T
radiotherapy T T
alone O T
in O O
anal D D
cancer D D
? O O

Standard T T
versus T T
high-dose T T
therapy T T
in O O
10+ O D
breast D D
cancer D D

Anal O D
continence O D
after O D
surgery T D
for O O
rectal D O
prolapse D O

Aspirin T T
therapy T T
for O O
cardiovascular D D
disease D D

Dosing O O
of O O
amoxicillin/clavulanate T O
for O O
treatment O O
of O O
lower D D
respiratory D D
tract D D
infection D D

Pharmacoeconomic O O
analysis O O
of O O
ampicillin-sulbactam T D
versus O D
cefoxitin T D
in O O
the O O
treatment O O
of O O
intraabdominal D D
infections D D

New T O
therapies T O
for O O
severe D D
meningococcal D D
disease D D

Another O O
potential O O
use O O
of O O
troglitazone T O
in O O
noninsulin-dependent D D
diabetes D D
mellitus D D

< O O
TO_SEE O O
> O O
Jaw D O
clenching D O
following O O
Gamma T O
Knife T O
treatment T O
for O O
trigeminal D D
neuralgia D D

The O O
protective O O
effect O O
of O O
condoms T O
and O O
nonoxynol-9 T D
against O D
HIV D D
infection D D

Evaluation O O
of O O
adjuvant T D
psychological T D
therapy T D
in O O
patients O O
with O O
testicular D D
cancer D D
: O O
randomised O O
controlled O O
trial O O

The O O
effect O O
of O O
an O O
endothelin-receptor T D
antagonist T D
, T O
bosentan T O
, O O
on O O
blood O O
pressure O O
in O O
patients O O
with O O
essential D D
hypertension D D
. O O

Guidelines O O
for O O
the O O
use O O
of O O
antiretroviral T D
agents T D
in O O
HIV D O
-infected O O
adults O O
and O O
adolescents O O

Long-term O T
therapy O T
with O O
long-acting T D
octreotide T D
( T D
Sandostatin-LAR T D
) T O
for O O
the O O
management O O
of O O
acromegaly D O

Are O O
ABVD T O
and O O
MOPP/ABV T O
truly O O
equivalent O O
for O O
treating O D
Hodgkin D D
's D D
disease D D
at O O
advanced O O
stages O O
? O O

Paclitaxel T O
for O O
the O O
treatment O O
of O O
lymphoma D D

Montelukast T O
, T O
a T O
leukotriene-receptor T O
antagonist T O
, T O
for O O
the O O
treatment O O
of O O
mild D D
asthma D D
and D O
exercise-induced D O
bronchoconstriction D O

Atypical O D
antipsychotic T D
agents T D
in O O
the O O
treatment O O
of O O
Schizophrenia D O
and D O
other D O
psychiatric D D
disorders D D

Percutaneous T T
transluminal T T
angioplasty T T
in O O
the O O
treatment O O
of O O
renovascular D D
hypertension D D
: O O
sequential O O
prospective O O
study O O

Esophageal T O
intubation T O
for O O
palliative O D
treatment O D
in O O
advanced D D
carcinoma D D
of D O
the D O
esophagus D O
and D O
cardia D O

Pathological O O
staging O O
and O O
biochemical O T
recurrence O T
after O T
neoadjuvant T T
androgen T T
deprivation T T
therapy T T
in O O
combination O O
with O O
radical T D
prostatectomy T D
in O O
clinically O D
localized O D
prostate D D
cancer D D

How O O
often O O
does O O
surgery T O
for O O
peptic D D
ulceration D D
eradicate O D
Helicobacter O D
pylori O D
? O O
Systematic O O
review O O
of O O
36 O O
studies O O

A O O
comparison O O
of O O
noninvasive T D
positive-pressure T D
ventilation T D
and O O
conventional T D
mechanical T D
ventilation T D
in O O
patients O O
with O O
acute D D
respiratory D D
failure D D

Long-term O O
safety O O
and O O
effectiveness O O
of O O
iron-chelation T T
therapy T T
with T O
deferiprone T O
for O O
thalassemia D D
major D D

Positron O D
emission O D
tomography O D
in O O
assessing O O
response O O
to O O
neoadjuvant T T
chemotherapy T T
for O O
non-small-cell D D
lung D D
cancer D D

Reconstruction O O
of O O
thoracic O D
wall O D
defects O D
after O D
tumor D D
resection T D
using O O
a O O
polytetrafluoroethylene O O
soft O O
tissue O O
( O O
Gore-Tex O O
) O O
patch O O

A O O
comparison O O
of O O
rectal T D
diazepam T D
gel T D
and O O
placebo O O
for O O
acute D D
repetitive D D
seizures D D

Effect O O
of O O
long-term O D
salmeterol T D
treatment T D
on O D
exercise-induced D D
asthma D D

Randomized O O
trial O O
of O O
intensive T D
cyclophosphamide T D
, T O
epirubicin T O
, T O
and T O
fluorouracil T T
chemotherapy T T
compared O T
with O O
cyclophosphamide T O
, T O
methotrexate T O
, T O
and T O
fluorouracil T O
in O O
premenopausal O O
women O O
with O O
node-positive D D
breast D D
cancer D D

Acute O O
effect O O
of O O
lorazepam T O
on O O
respiratory O D
muscles O D
in O O
patients O O
with O O
chronic D D
obstructive D D
pulmonary D D
disease D D

Low-molecular-weight T D
heparins T D
in O O
the O O
treatment O O
of O O
venous D D
thromboembolism D D

5-year O O
outcome O O
of O O
surgical T D
resection T D
and O O
watchful O O
waiting O O
for O O
men O O
with O O
moderately O D
symptomatic O D
benign D D
prostatic D D
hyperplasia D D
: O O
a O O
Department O O
of O O
Veterans O D
Affairs O D
cooperative O D
study O O

For O O
how O O
long O D
should O D
antipsychotic T D
medication T D
be O O
continued O O
after O O
the O O
first O O
psychotic D O
episode D O
in D O
schizophrenics D O
? O O

IDA-FLAG T O
( T O
idarubicin T O
, T O
fludarabine T O
, T O
cytarabine T O
, T O
G-CSF T O
) T O
, O O
an O O
effective O O
remission-induction T O
therapy T O
for O O
poor-prognosis D D
AML D D
of D O
childhood D D
prior O D
to O O
allogeneic O O
or O O
autologous O O
bone O O
marrow O D
transplantation O D
: O O
experiences O O
of O O
a O O
phase O O
II O O
trial O O

< O O
TO_SEE O O
> O O
Effects O O
of O O
anal T D
invasive T D
treatment T D
and O O
incontinence D O
on O O
mental O O
health O O
and O O
psychosocial O O
functioning O O
of O O
adolescents O O
with O O
Hirshsprung D D
's D D
disease D D
and O O
low O O
anorectal D D
anomalies D D

Single O O
or O O
double O D
lung T D
transplantation T D
for O O
pulmonary D D
hypertension D D

Interferon T O
beta T O
treatment T O
for O O
multiple D D
sclerosis D D

Ten-year O D
disease O D
free O O
survival O O
after O O
transperineal T D
sonography-guided T D
iodine-125 T D
brachytherapy T D
with O O
or O O
without O O
45-Gray T O
external T O
beam T O
irradiation T O
in O O
the O O
treatment O O
of O O
patients O O
with O O
clinically O D
localized O D
, O O
low O O
to O O
high O O
Gleason D D
grade D D
prostate D D
carcinoma D D

Partial O O
or O O
near O O
total O O
pancreatectomy T O
for O O
persistent D D
neonatal D D
hyperinsulinaemic D D
hypoglycaemia D D
: O O
the O O
pathologist O O
's O O
role O O

Radical T O
prostatectomy T O
for O O
prostate D D
cancer D D
: O O
the O O
perineal O O
approach O O
increases O O
the O O
risk O O
of O O
surgically O O
induced O O
positive O O
margins O O
and O O
capsular O O
incisions O O

Open T O
capsulorrhaphy T O
with T O
suture T O
anchors T O
for O O
recurrent D D
anterior D D
dislocation D D
of D O
the D O
shoulder D O

Intravenous T D
immunoglobulin T D
treatment T D
in O D
multiple D D
sclerosis D D

Randomised O O
trial O O
of O O
irinotecan T D
versus O D
fluorouracil T D
by O O
continuous O T
infusion O T
after O T
fluorouracil O T
failure O T
in O O
patients O O
with O O
metastatic D D
colorectal D D
cancer D D

The O O
effectiveness O O
of O O
intraocular T D
pressure T D
reduction T D
in O O
the O O
treatment O O
of O O
normal-tension D D
glaucoma D D

Perceived O O
contraindications O O
to O O
thrombolytic T O
treatment T O
in O O
acute D D
myocardial D D
infarction D D

Lignocaine T O
or O O
bupivacaine T O
for O O
digital D D
ring D D
block D D

Steroids T O
in O O
lateral D O
epicondylitis D O

Steroids T O
in O O
De D O
Quervain D D
's D D
tenosynovitis D D

Antibiotics T O
after O O
dog D O
bite D O

Immobilisation T O
after O O
first O O
anterior O O
shoulder D D
dislocation D D

Stereotactic T T
radiosurgery T T
for O O
acoustic D D
neuroma D D
: O O
a O O
Canadian O O
perspective O O

Anticytokine T D
therapy T D
-- O O
a O O
new O O
era O O
in O O
the O O
treatment O O
of O O
rheumatoid D D
arthritis D D
? O O

Control O O
of O O
the O O
malignant D D
hyperpyrexic D D
syndrome D D
in O O
MHS O O
swine O O
by O O
dantrolene T O
sodium T O

Hematopoietic T T
stem-cell T T
transplantation T T
for O O
the O O
treatment O O
of O O
severe D D
combined D D
immunodeficiency D D

Low-dose T O
clozapine T O
for O O
the O O
treatment O O
of O O
drug-induced D D
psychosis D D
in D D
Parkinson D D
's D D
disease D D

Comparing O O
the O O
efficacy O O
and O O
safety O O
of O O
fluoxetine T O
and O O
venlafaxine T O
in O O
outpatient D O
depression D O

Cost-effectiveness O O
of O O
interferon T O
treatment T O
for O O
hepatitis D D
C D D

Hyperbaric T T
oxygen T T
therapy T T
for O O
children O O
with O O
cerebral D D
palsy D D

Peripheral T T
retinal T T
cryotherapy T T
for O O
postvitrectomy D D
diabetic D D
vitreous D D
hemorrhage D D
in O O
phakic O O
patients O O

Hyperbaric T T
or T T
normobaric T T
oxygen T T
for O O
acute D D
carbon D D
monoxide D D
poisoning D D
: O O
a O O
randomised O O
controlled O O
clinical O O
trial O O

Multicentre O O
clinical O O
evaluation O O
of O O
vigabatrin T D
( T D
Sabril T D
) T D
in O O
mild D O
to D O
moderate D O
partial D O
epilepsies D O

Matrix T D
metalloproteinase T D
inhibitors T D
in O O
the O O
treatment O O
of O O
cancer D D

High O T
dose O T
cyclophosphamide T T
with O O
carboplatin T O
: O O
a O O
tolerable O O
regimen O O
suitable O O
for O O
dose O O
intensification O O
in O O
children O O
with O O
solid D D
tumors D D

Microsurgical T O
treatment T O
of O O
supratentorial D D
cavernous D D
malformations D D

Microsurgical T O
treatment T O
of O O
infratentorial D D
malformations D D

Stereotactic T T
radiosurgery T T
for O O
management O O
of O O
deep D D
brain D D
cavernous D D
malformations D D

Interferon-antibodies T O
and O O
the O O
breakthrough O T
phenomenon O T
during O T
ribavirin/interferon-alpha T T
combination T T
therapy T T
and O T
interferon-alpha T T
monotherapy T T
of O O
patients O O
with O O
chronic D D
hepatitis D D
C D D

Treatment O O
of O O
Barrett D D
esophagus D D
with O O
argon T D
plasma T D
coagulation T D
with T O
acid T O
suppression T O
-- O O
a O O
prospective O O
study O O

Meta-analysis O O
of O O
typhoid D D
vaccine T D
efficacy O D
trials O O
showed O O
that O O
whole O O
cell O O
vaccines O O
are O O
more O O
effective O O
than O O
either O O
the O O
oral O O
, O O
attenuated O O
vaccine O O
or O O
the O O
Vi O O
polysaccharide O O
vaccine O O

Experimental O D
vaccination T D
against O D
Mycoplasma D D
agalactiae D D
using O D
different O D
inactivated O D
vaccines O D

A O O
randomized O O
, O O
controlled O O
study O O
in O O
adults O O
of O O
the O O
immunogenicity O O
of O O
a O O
novel O D
hepatitis D D
B D O
vaccine T O
containing O O
MF59 O O
adjuvant O O

Immunogenicity O O
of O O
three O O
Haemophilus D D
influenzae D D
type D D
b D O
protein O O
conjugate O O
vaccines T O
in O O
HIV O O
seropositive O O
adults O O
and O O
analysis O O
of O O
predictors O O
of O O
vaccine O D
response O D

Vaccination T D
against O D
Schistosoma D D
mansoni D D
infection D D
using O D
74 O O
kDa O O
Schistosoma O O
protein O O
antigen O O

Phase O O
1 O O
safety O O
and O O
immune O O
response O O
studies O O
of O O
a O O
DNA T O
vaccine T D
encoding O D
hepatitis D D
B D O
surface O O
antigen O O
delivered O O
by O O
a O O
gene O O
delivery O O
device O O

Protection O O
of O O
swine O D
from O D
foot-and-mouth D D
disease D D
with O O
one O O
dose O O
of O O
an O O
all-D T O
retro T O
peptide T O

Intranasal T D
immunization T D
with O O
Chlamydia D D
trachomatis D D
, D O
serovar D O
E D O
, O O
protects O O
from O O
a O O
subsequent O O
vaginal O O
challenge O O
with O O
the O O
homologous O O
serovar O O

Mutants O O
of O O
cholera O D
toxin O D
as O O
an O O
effective O O
and O O
safe O O
adjuvant O O
for O O
nasal D D
influenza D D
vaccine T D

Field O O
evaluation O O
of O O
the O O
clinical O O
effectiveness O O
of O O
vaccines T D
against O D
pertussis D D
, D O
measles D O
, D O
rubella D O
and D O
mumps D O
: O O
comments O O

Transmural T O
drainage T O
of O O
pancreatic D D
fluid D D
collections D D
without O O
electrocautery O O
using O O
the O O
Seldinger O O
technique O O

Echocardiography-guided T T
ethanol T T
septal T T
reduction T T
for O O
hypertrophic D D
obstructive D D
cardiomyopathy D D

Alterations O O
of O O
monocyte O D
function O D
in O O
patients O O
with O O
growth D D
hormone D D
( D D
GH D D
) D D
deficiency D D
: O O
effect O O
of O O
substitutive O D
GH T D
therapy T D

Comparison O O
of O O
the O O
effects O O
of O O
salmeterol T O
and O O
ipratropium T D
bromide T D
on O O
exercise O O
performance O O
and O O
breathlessness O O
in O O
patients O O
with O O
stable D D
chronic D D
obstructive D D
pulmonary D D
disease D D
. O O

< O O
TO_SEE O O
> O O
Safety O O
trial O O
with O O
the O O
5HT1B/1D T O
agonist T O
avitriptan T O
( O O
BMS-180048 O O
) O O
in O O
patients O O
with O O
migraine D O
who O O
have O O
experienced O O
pressure D O
, D O
tightness D O
, D O
and/or D O
pain D O
in O O
the O O
chest O O
, O O
neck O O
, O O
and/or O O
throat O O
following O O
sumatriptan T O

Double O O
blind O O
, O O
cluster O O
randomised O O
trial O O
of O O
low O O
dose O O
supplementation O O
with O O
vitamin T O
A T O
or O O
beta T O
carotene T O
on O O
mortality D O
related D O
to D O
pregnancy D O
in O O
Nepal O O
. O O

Medical T O
treatments T O
for O O
balding D O
in O O
men O O

Carbon D T
monoxide D T
poisoning D T
treated O O
with O O
hyperbaric T D
oxygen T D
: O O
metabolic O O
acidosis O O
as O O
a O O
predictor O O
of O O
treatment O O
requirements O O

Medication T O
received O O
by O O
patients O O
with O O
depression D D
following O D
the O O
acute O O
episode O O
: O O
adequacy O O
and O O
relation O O
to O O
outcome O O

< O O
TO_SEE O O
> O O
Reduced D O
bone D O
density D O
at O O
completion O O
of O O
chemotherapy T O
for O O
a O O
malignancy D O

< O O
TO_SEE O O
> O O
Surgical-site D T
complications D T
associated O T
with O O
a O O
morphine T D
nerve T D
paste T D
used O O
for O O
postoperative D D
pain D D
control D D
after D D
laminectomy D D

Splenectomy T T
during O T
pregnancy O T
: O O
an O O
option O O
in O O
the O O
treatment O O
of O O
autoimmune D D
thrombocytopenic D D
purpura D D

Melatonin T O
treatment T O
of O O
sleep-wake D D
cycle D D
disorders D D
in O O
children O O
and O O
adolescents O O

Randomized O O
phase O O
II O O
study O O
of O O
the O O
neurokinin T O
1 T O
receptor T O
antagonist T O
CJ-11 T O
, T O
974 T O
in O O
the O O
control O O
of O O
cisplatin-induced D O
emesis D O

Cataract D O
surgery T O
and O O
its O O
effect O O
on O O
intraocular O O
pressure O O

The O O
outcome O O
of O O
arthroscopic T O
treatment T O
of O O
temporomandibular D D
joint D D
arthropathy D D

Neostigmine T O
for O O
acute D D
colonic D D
pseudo-obstruction D D

New O O
vaccine T O
targets O O
childhood D O
pneumonia D O

A O O
comparison O O
of O O
botulinum T O
toxin T O
and O O
nitroglycerin T O
ointment T O
for O O
chronic D D
anal D D
fissure D D

< O O
TO_SEE O O
> O O
The O O
effect O O
of O O
bisoprolol T O
on O O
perioperative D O
mortality D O
and O O
myocardial D D
infarction D D
in O O
high-risk O D
patients O D
undergoing O D
vascular T D
surgery T D

Surgical T O
management T O
of O O
severe D D
secondary D D
peritonitis D D

Early T O
surgical T O
treatment T O
for O O
supratentorial D D
intracerebral D D
hemorrhage D D
: O O
a O O
randomized O O
feasibility O O
study O O

Evaluation O O
of O O
clomipramine T O
as O O
an O O
adjunct O O
to O O
behavioural T T
therapy T T
in O O
the O O
treatment O O
of O O
separation-related D D
problems D D
in O O
dogs O O

NICE O O
to O O
rule O O
on O O
influenza D D
flu D D
drug O D
zanamivir T D

< O O
TO_SEE O O
> O O
Longitudinal D D
melanonychia D D
associated O D
with O O
hydroxyurea T D
therapy T D
in O O
a O O
patient O O
with O O
essential D D
thrombocytosis D D

Biologic O O
markers O O
as O O
predictors O O
of O O
clinical O T
outcome O T
from O T
systemic T T
therapy T T
for O O
primary O D
operable O D
breast D D
cancer D D

Treatment O O
of O O
hypertension D D
with O O
ascorbic T D
acid T D

Postoperative D D
peritonitis D D
originating O D
from O D
the O O
duodenum O O
: O O
operative O O
management O O
by O O
intubation T O
and T O
continuous T O
intraluminal T O
irrigation T O

Efficacy O O
of O O
open-bite D D
treatment O D
with O O
the O O
Thera-spoon T O

< O O
TO_SEE O O
> O O
Pompholyx D O
( D O
vesicular D O
eczema D O
) D O
after O O
i.v T O
. T O
immunoglobulin T T
therapy T T
for O O
neurologic D D
disease D D

Mitomycin T O
, T O
ifosfamide T O
, T O
and T O
cisplatin T O
in O O
unresectable D D
non-small-cell D D
lung D D
cancer D D
: O O
effects O O
on O O
survival O O
and O O
quality O O
of O O
life O O
. O O

Hepatic O O
arterial O O
infusion O O
of O O
chemotherapy T D
after O D
resection T D
of O O
hepatic D D
metastases D D
from O D
colorectal D D
cancer D D

Waiting O O
for O O
the O O
definitive O O
trial O O
of O O
hepatic T D
arterial T D
chemotherapy T D
for O O
colorectal D D
cancer D D

Phase O O
III O O
randomized O O
study O O
of O O
cisplatin T T
versus O T
paclitaxel T T
versus O T
cisplatin T T
and T O
paclitaxel T O
in O O
patients O O
with O O
suboptimal O D
stage O D
III O D
or O D
IV O D
ovarian D D
cancer D D
: O O
a O O
gynecologic O O
oncology O O
group O O
study O O

Evidence O O
for O O
double O O
resistance O O
to O O
permethrin T O
and T O
malathion T O
in O O
head D O
lice D O

Urgent O O
colonoscopy T O
for O O
the O O
diagnosis O O
and O O
treatment O O
of O O
severe D D
diverticular D D
hemorrhage D D

Treatment O O
of O O
Parkinson D D
's D D
disease D D
should O D
begin O D
with O O
a O O
dopamine T D
agonist T D

< O O
TO_SEE O O
> O O
Ulceration D O
in O O
an O O
ileocolic D D
anastomosis D D
treated O O
with O O
ranitidin T O

Low-molecular-weight T D
heparin T D
vs O O
heparin T O
in O O
the O O
treatment O O
of O O
patients O O
with O O
pulmonary D D
embolism D D

Radiotherapy T O
in O O
breast-conserving T D
treatment T D
for O O
ductal D D
carcinoma D D
in O O
situ O O
: O O
first O O
results O O
of O O
the O O
EORTC O O
randomised O O
phase O O
III O O
trial O O
10853 O O

Methadone T O
maintenance T O
vs O O
180-day O D
psychosocially O D
enriched O D
detoxification T D
for O O
treatment O O
of O O
opioid D D
dependence D D
: O O
a O O
randomized O O
controlled O O
trial O O

Cryogen O D
spray O D
cooling O D
during O D
Nd T D
: T O
YAG T O
laser T O
treatment T O
of O O
hemangiomas D O

Effects O O
of O O
tolcapone T O
, T O
a T O
catechol-O-methyltransferase T O
inhibitor T O
, O O
on O O
motor O O
symptoms O O
and O O
pharmacokinetics O O
of O O
levodopa T O
in O O
patients O O
with O O
Parkinson D D
's D D
disease D D
. O O

Gene T O
therapy T O
for O O
cancer D D

Therapeutic O O
effects O O
of O O
LDL T O
apheresis T O
in O O
the O O
prevention O O
of O O
atherosclerosis D O

Dry T O
powdered T D
formoterol T D
, O O
twice O O
a O O
day O O
versus O O
aerosolized T O
salbutamol T O
, O O
four O O
times O O
a O O
day O O
, O O
in O O
patients O O
with O O
stable D D
asthma D D

Cell-based T D
vaccination T D
against O D
melanoma D D
-- O O
background O O
, O O
preliminary O O
results O O
, O O
and O O
perspective O O

Celecoxib T O
for O O
arthritis D O

Poliomyelitis D O
prevention O O
: O O
revised O O
recommendations O O
for O O
use O O
of O O
inactivated O O
and O O
live O O
oral O D
poliovirus D D
vaccines T D

Mesh O O
plug O O
repair O O
and O O
groin D D
hernia D D
surgery T D

Brimonidine T D
tartrate T D
0.2 O D
% O O
twice O O
daily O O
vs O O
timolol T O
0.5 O O
% O O
twice O O
daily O O
: O O
1-year O O
results O O
in O O
glaucoma D O
patients O O

Ticarcillin/clavulanate T T
versus O T
imipenem/cilistatin T T
for O O
the O O
treatment O O
of O O
infections D D
associated D D
with D O
gangrenous D O
and D O
perforated D D
appendicitis D D

Is O O
zero O O
dose O O
oral O O
polio D O
vaccine T O
effective O O
in O O
preterm O O
babies O O
? O O

An O O
economic O O
analysis O O
of O O
different O O
strategies O O
of O O
immunization T D
against O D
hepatitis D D
A D O
virus D O
in O O
developed O O
countries O O

Issues O O
and O O
challenges O O
with O O
antithrombotic T D
therapy T D
in O O
diabetic O O
patients O O
with O O
acute D D
coronary D D
syndromes D D

Global O O
risk O O
assessment O O
for O O
lipid T O
therapy T O
to O O
prevent O D
coronary D D
heart D D
disease D D

The O O
role O O
of O O
fibric T O
acid T O
derivatives T O
in O O
the O O
secondary O O
prevention O O
of O O
coronary D D
heart D D
disease D D

Epoetin T O
: O O
a O O
pharmacoeconomic O O
review O O
of O O
its O O
use O O
in O O
chronic D D
renal D D
failure D D
and O O
its O O
effects O O
on O O
quality O O
of O O
life O O

Rationale O O
for O O
the O O
use O O
of O O
antiplatelet T D
drugs T D
in O O
patients O O
with O O
peripheral D D
vascular D D
disease D D

The O O
fluoroquinolones T O
for O O
urinary D D
tract D D
infections D D
: O O
a O O
review O O

Reduction O O
of O O
vasoreactivity D O
and O O
thrombogenicity D O
with O O
laser-thermal T D
angioplasty T D
: O O
comparison O O
with O O
balloon T D
angioplasty T D

Effects O O
of O O
ultrasound T O
energy T O
on O O
total D O
peripheral D O
artery D O
occlusions D O
: O O
initial O O
angiographic O O
and O O
angioscopic O O
results O O
. O O

High-dose T T
chemotherapy T T
with T O
autologous T T
stem-cell T T
support T T
for O O
epithelial D D
ovarian D D
cancer D D

Pelvic T D
floor T D
stimulation T D
in O O
the O O
treatment O O
of O O
adult D D
urinary D D
incontinence D D

Chronic T D
vagus T D
nerve T D
stimulation T D
for O O
treatment O O
of O O
seizures D O

`` T O
Tandem T O
'' T O
high-dose T O
chemoradiotherapy T O
with T O
autologous T D
stem-cell T D
support T D
in O O
the O O
treatment O O
of O O
newly O O
diagnosed O O
or O O
responsive O O
multiple D O
myeloma D O

Special O O
report O O
: O O
comparative O O
efficacy O O
of O O
different O O
types O O
of O O
pneumatic T D
compression T D
pumps T D
for O O
the O O
treatment O O
of O O
lymphedema D O

Special O O
report O O
: O O
pressure-reducing T O
support T O
surfaces T O
in O O
the O O
prevention O O
and O O
treatment O O
of O O
pressure D D
ulcers D D
: O O
group O O
1 O O
technologies O O

Intravenous T O
immune T O
globulin T O
for O O
recurrent D D
spontaneous D D
abortion D D

External T O
counterpulsation T O
for O O
treatment O O
of O O
chronic D D
stable D D
angina D D
pectoris D D

Intra-articular T T
hyaluronan T T
injections T T
for O O
treatment O O
of O O
osteoarthritis D O
of O O
the O O
knee O O

Pneumococcal D O
vaccine T O
: O O
a O O
second O O
look O O

